Analyst Ratings February 9, 2026

Cantor Fitzgerald Sticks With Overweight on Ventas, Sees Room for Further Upside

Analyst reaffirms $93 target after Ventas posts strong Q4 2025 results and projects continued SHOP growth in 2026

By Hana Yamamoto VTR
Cantor Fitzgerald Sticks With Overweight on Ventas, Sees Room for Further Upside
VTR

Cantor Fitzgerald reiterated its Overweight rating and $93 price target on Ventas (NYSE: VTR) following the REIT’s fourth-quarter 2025 results and 2026 outlook. The firm highlighted robust same-store NOI expansion in the Senior Housing Operating Portfolio (SHOP) and raised optimism for potential upside, while noting valuation and sustainability caveats.

Key Points

  • Cantor Fitzgerald reiterates Overweight rating and $93 price target on Ventas after Q4 2025 results and 2026 outlook.
  • Ventas reported 15% same-store NOI growth in SHOP for 2025 and guided to the same rate in 2026; overall revenue rose 18.99% over the last twelve months.
  • Ventas beat Q4 EPS and revenue estimates, amended its ATM agreement to $2.5 billion capacity, and has a 28-year dividend payment history with a 2.52% yield.

Cantor Fitzgerald has reaffirmed an Overweight rating and a $93.00 price target on Ventas (NYSE:VTR) after the healthcare real estate investment trust released fourth-quarter 2025 results and a 2026 outlook. The stock was trading at $82.55 at the time of the report, narrowly below its 52-week high of $82.80, and has delivered a 40.08% total return over the past year.

The research note emphasized Ventas’s performance in its Senior Housing Operating Portfolio (SHOP), where the company reported 15% same-store net operating income (NOI) growth during 2025 and issued guidance for the same 15% rate in 2026. Cantor Fitzgerald linked this segment-level momentum to the company’s broader revenue strength, noting overall revenue growth of 18.99% in the trailing twelve months.

Cantor Fitzgerald characterized Ventas’s forward-looking stance as "an effective balance between the present opportunity and the potential for future upside," and suggested the company may be positioned to exceed expectations and raise guidance in upcoming quarters. The note also cited a strong Wall Street consensus, with an aggregate analyst rating of 1.52, reflecting generally favorable sentiment toward the $39.49 billion healthcare REIT.

The SHOP business is central to the thesis: it accounts for 53% of Ventas’s NOI and, according to the firm, is benefiting from demographic tailwinds as the baby-boomer cohort reaches their eighth decade. Cantor Fitzgerald also observed that supply pressure in the segment remains limited, supporting near-term operating leverage.

Dividend continuity and yield were also highlighted. Data from InvestingPro indicate Ventas has paid dividends for 28 consecutive years and currently offers a yield of 2.52%, a point of interest for income-focused investors.


Valuation and prudence

While Cantor Fitzgerald encouraged investors to "ride the SHOP wave," the firm cautioned that double-digit organic growth is unlikely to persist indefinitely. Complementing this caution, InvestingPro’s Fair Value assessment in the referenced data set suggests the stock is trading above its assessed fair value at current levels, a signal that investors should weigh valuation when sizing positions.

Recent operating and financing developments

Ventas posted fourth-quarter 2025 financial results that beat consensus on both the top and bottom lines. The company reported earnings per share of $0.15, versus a forecast of $0.10 - a 50% surprise - and revenue of $1.57 billion compared with an expected $1.5 billion.

On the capital markets front, Ventas amended its at-the-market (ATM) sales agreement to raise the capacity for common stock issuance to $2.5 billion. The amendment names several financial institutions as sales agents and adds M&T Securities, Inc. as a new participant to the program.

Separate analyst movement noted alongside the Cantor Fitzgerald update included Evercore ISI raising its price target on Ventas to $90.00 from $86.00 and maintaining an Outperform rating, citing the SHOP segment’s strong showing.


Takeaway

Cantor Fitzgerald’s reaffirmation of an Overweight view and $93 target rests on durable SHOP performance, notable same-store NOI gains, and a top-line acceleration approaching 19% year-over-year. The firm’s guidance and commentary point to potential upside, but both the firm and InvestingPro data flag valuation and sustainability considerations that investors should monitor.

Risks

  • Valuation risk: InvestingPro’s Fair Value assessment indicates the stock may be overvalued at current levels, introducing downside risk for investors.
  • Sustainability risk: Cantor Fitzgerald warns that double-digit organic growth in the SHOP segment is unlikely to be sustainable indefinitely, posing a risk to future operating momentum.
  • Financing/dilution risk: The amendment increasing the at-the-market common stock capacity to $2.5 billion could pressure the share base if utilized, affecting returns to equity investors.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026